Notice of Appeal

Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]

NICE has received 4 appeals, that fall within one or more of the two strictly limited grounds for appeal, against the Final Draft Guidance on the above technology from the following organisations:

  • British Association of Dermatologists
  • Incyte Biosciences UK Ltd
  • The Vitiligo Society
  • Vitiligo Support UK

The appeal panel will convene on Friday 11 October at 10:00am via Zoom to hear oral representations from the appellants.

Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing.

Where possible, requests to attend should be made using the registration link that will be available on our website from 14 August 2024. The registration period for this appeal will end at 4:00pm on Friday 4 October.

Further details relating to public attendance at this appeal are available on the same webpage as above.